AB-1001
From Wikipedia, the free encyclopedia
Experimental gene therapy
AB-1001 is an experimental gene therapy developed for Huntington's disease. It is intended to increase the production of the CYP46A1 enzyme and cholesterol levels in the brain.[1] [2]
References
[edit ]- ↑ Parkin, Georgia M.; Corey-Bloom, Jody (2023). "Considerations and Advances in Huntington's Disease Clinical Trial Design". Biomarkers for Huntington's Disease: Improving Clinical Outcomes. Springer International Publishing. pp. 405–431. doi:10.1007/978-3-031-32815-2_17. ISBN 978-3-031-32815-2.
- ↑ Schultz, Meredith; Durr, Alexandra; Karachi, Carine; O’Callaghan, Michael; Alves, Sandro; Lamontagne, Alain; Hurmic, Hortense; Cartier, Nathalie (25 April 2023). "Investigating the Effects of Brain Cholesterol Metabolism Using CYP46A1 Gene Therapy in Subjects with Huntington's Disease (P1-11.016)" . Neurology. 100 (17 Supplement 2). doi:10.1212/WNL.0000000000203493. ISSN 0028-3878. S2CID 258404880.
Retrieved from "https://en.wikipedia.org/w/index.php?title=AB-1001&oldid=1292608173"